Allevio is very proud to have organized and received IRB approval for a study which considers IV Lidocaine infusion therapy for different kinds of Neuropathic pain.
Allevio has been offering IV Lidocaine infusion treatments for over 5 years, and has seen many of our patients find success with this treatment. The infusion itself is covered under OHIP (but the lidocaine itself is not), and has anecdotally (i.e. we have seen but not measured the results in a scientifically controlled way) shown us a very promising future for this type of pain relief.
After seeing so much anecdotal success, Allevio has decided to design an IRB-approved, independent, prospective and observational study to assess the quality of life of patients with chronic pain who receive intravenous lidocaine and ketamine infusions.
We have started recruiting patients who have various sources of pain. As long as a patient meets the inclusion criteria and suffers from a form of neuropathic pain, they can be part of this very exciting study.
We are currently looking for patients with neuropathic pain for our study. This can include but it not limited to patients who have:
- Fibromyalgia
- Diabetic Neuropathy
- Peripheral Neuropathy
- Cancer-rated or Cancer treatment-related pain conditions
- Post-Operative nerve pain or neuropathic pain
This study has no 3rd party sponsor.
If you would like to be considered for this study, please give the Doctor Letter Lidocaine Ketamine Study to your physician, and ask them to complete an Allevio Referral and send it to us, marking on the form that you are interested in the study. If you are a physician interested to learn more or refer into the study, please email us to be connected to the study and research leads.